Severely calcified coronary artery lesions are encountered increasingly frequently in clinical practice. The technical challenges faced by the interventional cardiologist in the treatment of these ...

Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) ...

Abbott begins new Intravascular Lithotripsy trial to improve outcomes in patients with coronary artery disease: Abbott Park, Illinois Wednesday, March 26, 2025, 15:00 Hrs [IST] Ab ...

MiRus is pleased to announce the launch of the US multi-center Early Feasibility Study of the Siegel™ 8-Fr aortic ...

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

Purpose: The role of vitamin K in the prevention and treatment of osteoporosis and arterial calcification is examined. Summary: Vitamin K is essential for the activation of vitamin K-dependent ...

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott (ABT) announced that the U.S. Food and Drug Administration, FDA, has approved an investigational device exemption, IDE, for its Coronary ...

Abbott received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy (IVL) system.

• Ultrasound guidance may lead to a higher first-attempt success rate and improved time to successful common femoral artery (CFA) access, while reducing the venipuncture rate (unintentionally ...